BioNTech SE (BNTX)
84.64
-1.24
(-1.44%)
USD |
NASDAQ |
Jun 21, 16:00
84.64
0.00 (0.00%)
After-Hours: 20:00
BioNTech Cash from Operations (Quarterly): -344.65M for March 31, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -344.65M |
| December 31, 2023 | 893.27M |
| September 30, 2023 | 877.10M |
| June 30, 2023 | 4.772B |
| March 31, 2023 | -727.55M |
| December 31, 2022 | 1.476B |
| September 30, 2022 | 4.354B |
| June 30, 2022 | 3.944B |
| March 31, 2022 | 4.545B |
| December 31, 2021 | -231.55M |
| September 30, 2021 | 1.780B |
| Date | Value |
|---|---|
| June 30, 2021 | -120.93M |
| March 31, 2021 | -375.12M |
| December 31, 2020 | 291.78M |
| September 30, 2020 | -229.89M |
| June 30, 2020 | -16.95M |
| March 31, 2020 | -60.36M |
| December 31, 2019 | -72.21M |
| September 30, 2019 | -53.75M |
| June 30, 2019 | -60.80M |
| March 31, 2019 | -35.46M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-727.55M
Minimum
Mar 2023
4.772B
Maximum
Jun 2023
1.032B
Average
-35.35M
Median
Cash from Operations (Quarterly) Benchmarks
| Pfizer Inc | 1.09B |
| Moderna Inc | -989.00M |
| Cellectis SA | -23.32M |
| Biodexa Pharmaceuticals Plc | -- |
| NuCana PLC | -7.462M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -2.503B |
| Cash from Financing (Quarterly) | -8.472M |
| Free Cash Flow | 5.344B |
| Free Cash Flow Per Share (Quarterly) | -2.051 |
| Free Cash Flow to Equity (Quarterly) | -506.34M |
| Free Cash Flow to Firm (Quarterly) | -493.35M |
| Free Cash Flow Yield | 26.27% |